Covid-19 vaccine update
Sign up for myFT Daily Digest and be the first to learn about the Covid-19 vaccine news.
Sinopharm is developing a local mRNA inoculant against Covid-19, becoming one of the first large Chinese pharmaceutical groups to adopt this technology to combat the disease.
The move of the state-owned pharmaceutical group coincides with the timing Increased worries The efficacy of traditional inactivated virus vaccines, these vaccines dominate the promotion in China. Some studies have shown that jabs produce fewer antibodies compared to mRNA injections.
Inactivated vaccines, such as the existing Covid vaccine of Sinopharm, use dead virus particles to generate an immune response, while the mRNA jab Contains genetic instructions Tell the cell to make viral proteins to activate the immune system.
Sinopharm is not the only Chinese company developing its own mRNA vaccine. The smaller manufacturer Walvax Biotechnology is already conducting trials.
However, the entry of large companies such as Sinopharm Holdings into the mRNA market may significantly promote the development of this technology in China.
“They are working hard to develop these… next-generation vaccines, because the first-generation vaccines must be bolstered and may have to be injected regularly,” said Jin Dongyan, a virologist at the University of Hong Kong. “MRNA vaccines are much more effective than inactivated vaccines.”
The German pharmaceutical company BioNTech, which cooperates with distribution partners Pfizer and China Fosun Pharma to provide mRNA vaccines, has also targeted the Chinese market and is Waiting for formal approval Jab from Beijing.
Zhu Jingjin, secretary of the Party Committee of China National Biotechnology Group, a subsidiary of Sinopharm Group, said that the company is developing an mRNA vaccine and a broad-spectrum recombinant protein vaccine that is undergoing clinical trials.Recombinant protein injection Target spike protein Viruses are used to enter and infect human cells.
“We have developed [the] Delta and Beta versions,” Zhu told Chinese official media at the China International Trade in Services Expo in Beijing. He added that the Phase I and Phase II clinical trials of recombinant protein injection have been completed.
China has received more than 2 billion doses of vaccines, most of which are inactivated vaccines developed by Sinopharm and another private biotechnology group, Huaxing.
These vaccines can be stored at higher temperatures than mRNA vaccines and have been approved by the World Health Organization Emergency use And has been shipped to more than 100 countries.
But many countries are studying Whether to protect By combining an inactivated virus vaccine with another vaccine with a higher efficiency (such as a vaccine using mRNA technology), the resistance to serious infections can be improved.
Sinopharm Vaccine Phase III Trial Shows Effectiveness 79% If the injections are given three weeks apart, they can fight the symptomatic Covid infection. The effective rate of BioNTech injection is 95%.
Cambodia stated that it will provide a third dose of AstraZeneca vaccine to frontline staff who have received Sinopharm or Kexing. Adenovirus vector vaccine.
Walvax said in a stock exchange document last week that it has received approval from the governments of Mexico and Indonesia to conduct phase 3 trials of its mRNA drug candidates. The lens is being jointly developed with Suzhou Aiboyuan Biosciences Company in China and the Chinese Academy of Military Sciences.